Stock Forecast Chart
Stock Price Prediction Summary
Forecast Score Based on 2 Weeks
Based on our forecast, the price of TRDA will rise by +9.65% over the next 2 Weeks and hit $8.03 by Wednesday, July 22, 2026. In that time frame, TRDA's share price is expected to range between $7.66 and $8.39.
BearishAverageBullish| Date | Predicted Lower | Predicted | Predicted Upper |
|---|---|---|---|
| Jul 22, 2026 | 7.66 | 8.03 | 8.39 |
| Jul 21, 2026 | 7.55 | 7.91 | 8.28 |
| Jul 20, 2026 | 7.54 | 7.93 | 8.30 |
| Jul 17, 2026 | 7.68 | 8.07 | 8.44 |
| Jul 16, 2026 | 7.57 | 7.94 | 8.31 |
| Jul 15, 2026 | 7.38 | 7.73 | 8.10 |
| Jul 14, 2026 | 7.25 | 7.62 | 8.00 |
| Jul 13, 2026 | 7.28 | 7.64 | 8.04 |
| Jul 10, 2026 | 7.39 | 7.78 | 8.17 |
| Jul 9, 2026 | 7.27 | 7.65 | 8.02 |
TRDA shares fell -1.74% in Wednesday, July 8, 2026's trading session, dropping from a previous close of $7.45 to move at $7.32. The stock demonstrated notable intraday movement (see TRDA's key stats for a full breakdown), fluctuating between $6.88 and $7.50, a +9.01% trading range. While recent weeks have seen some volatility, TRDA has managed to secure a -2.92% drop over the past 2 weeks. The downward price movement was accompanied by increased trading volume, with approximately 540.99K shares changing hands, 166.45K more than the previous session. This amounted to $3.96M in total market activity.
Will TRDA Continue Its Upward Trend?
According to analyst ratings and projections for TRDA, Entrada Therapeutics, Inc. shares are anticipated to increase by +12.78%, potentially reaching $8.39 per share by July 22, 2026. Short-term technical indicators currently suggest a neutral sentiment for TRDA. For deeper insights, view our sentiment analysis on AAPL covering social and institutional perspectives. However, the stock has recorded 16 positive trading days within the past 30 sessions. Based on the TRDA stock forecast, now is a good time to buy TRDA stock because its current trading price is -8.80% below our predicted value, hinting at a possible overvaluation. For deeper insights, view our sentiment analysis on TRDA covering social and institutional perspectives.
TRDA Technical Momentum: Overbought, Oversold, or Neutral?
An analysis of Relative Strength Index (RSI) indicators provides insight into TRDA's momentum. Short-term RSIs (9, 14, and 20-day figures ranging from 46.06% to 50.22%) suggest the stock is in a neutral to slightly bearish momentum phase. The 50-day RSI, at 45.08%, suggests a neutral medium-term outlook. Additionally, the 100-day RSI, at 46.85%, maintains a neutral outlook for the long term. Insights into TRDA's shareholder base show how institutional investors are positioning themselves during these momentum shifts
Entrada Therapeutics Short-Term Forecasts
TRDA Forecast For Next 5 Days
Our algorithm anticipates Entrada Therapeutics (TRDA) stock could hit $6.86 by Jul 15, 2026. This represents a -6.32% rise from today's price, following a +6.73% change over the past five days.
TRDA Forecast For Next 30 Days
Based on analysis of market trends, the outlook for Entrada Therapeutics, Inc. (TRDA) stock over the next 30 days is largely negative. Price forecasts suggest an average target of $5.77, which would mean a -21.17% decrease from the current price of $7.32. Projections for this period range from a high of $9.92 to a low of $1.76.
TRDA Forecast For Next 90 Days
Our proprietary market analysis suggests predictions for Entrada Therapeutics's price over the next three months point to a rise. TRDA stock is expected to peak at $15.57 on Jul 16, 2026 before potentially dipping to $9.72 on Sep 10, 2026. On average, TRDA is likely to trade around $12.55 in the coming 90 days.
Entrada Therapeutics Stock Forecast 2025
Based on our predictive models, Entrada Therapeutics (TRDA) is expected to trade between $9.72 and $23.47 throughout 2026. This would result in an average price of $14.02, potentially offering investors a +91.53% return from current levels.
Entrada Therapeutics, Inc. Monthly Forecast 2026–2027
July 2026
According to our latest forecast models, Entrada Therapeutics, Inc. (TRDA) is positioned to show a strong performance in July 2026. The price is predicted to move between $13.49 and $15.57, settling at an average of $14.56. This could translate to a +98.91% gain.
August 2026
Based on current market signals, Entrada Therapeutics, Inc. is projected to trend august 2026. We forecast a trading range from $10.71 to $13.44, with a likely average price of $11.72. Investors could expect a potential return of +60.11%.
September 2026
Our predictive algorithms indicate Entrada Therapeutics, Inc. stock may see a shift in September 2026. The expected range spans $9.72–$14.26, with an average target of $11.80. This represents a positive outlook and a possible gain of +61.20%.
October 2026
Analyzing established trends, Entrada Therapeutics, Inc. looks set to move in October 2026. Projections place the stock between $10.05 and $14.20, averaging around $11.76. This suggests a +60.66% gain from current levels.
November 2026
Market indicators suggest Entrada Therapeutics, Inc. could experience notable changes during November 2026. Prices could fluctuate within $11.24 to $18.42, with a midpoint forecast of $15.07. The stock might deliver a +105.87% gain.
December 2026
Forecasting for December 2026, models estimate that Entrada Therapeutics, Inc. may undergo key fluctuations. If trends hold, the stock might trade between $13.78 and $23.47, averaging $19.06. This signals a positive trajectory with potential returns around +160.38%.
January 2027
According to our latest forecast models, Entrada Therapeutics, Inc. (TRDA) is positioned to show a strong performance in January 2027. The price is predicted to move between $12.91 and $23.81, settling at an average of $19.54. This could translate to a +166.94% gain.
February 2027
Based on current market signals, Entrada Therapeutics, Inc. is projected to trend february 2027. We forecast a trading range from $13.09 to $29.47, with a likely average price of $22.31. Investors could expect a potential return of +204.78%.
March 2027
Our predictive algorithms indicate Entrada Therapeutics, Inc. stock may see a shift in March 2027. The expected range spans $9.89–$29.21, with an average target of $21.93. This represents a positive outlook and a possible gain of +199.59%.
April 2027
Analyzing established trends, Entrada Therapeutics, Inc. looks set to move in April 2027. Projections place the stock between $7.57 and $28.44, averaging around $21.03. This suggests a +187.30% gain from current levels.
May 2027
Market indicators suggest Entrada Therapeutics, Inc. could experience notable changes during May 2027. Prices could fluctuate within $4.49 to $27.27, with a midpoint forecast of $17.42. The stock might deliver a +137.98% gain.
June 2027
Forecasting for June 2027, models estimate that Entrada Therapeutics, Inc. may undergo key fluctuations. If trends hold, the stock might trade between $2.74 and $23.66, averaging $14.58. This signals a positive trajectory with potential returns around +99.18%.
July 2027
According to our latest forecast models, Entrada Therapeutics, Inc. (TRDA) is positioned to show a strong performance in July 2027. The price is predicted to move between $2.59 and $24.82, settling at an average of $14.87. This could translate to a +103.14% gain.
TRDA's history of dividends and stock splits also plays a role in long-term investor confidence.